Picture of Sartorius Stedim Biotech SA logo

DIM — Sartorius Stedim Biotech SA News Story

0.000.00%
fr flag iconLast trade - 00:00
HealthcareSpeculativeLarge CapHigh Flyer

Brief: Sartorius 9-Month Operating EBITDA Margin At 28.8%

Oct 19 (Reuters) - SARTORIUS AG  SATG.DE :
    * SARTORIUS NINE-MONTH FIGURES: NORMALIZATION OF DEMAND
AFTER THE
END OF THE PANDEMIC CONTINUES
    * SALES ADJUSTED FOR EXCHANGE RATE EFFECTS -16.4 PERCENT,
EXCLUDING CORONA BUSINESS DECLINE OF JUST OVER 10 PERCENT
    * OPERATING EBITDA MARGIN AT 28.8 PERCENT
    * CUSTOMER INVENTORY REDUCTION AFTER THE END OF THE PANDEMIC
IS
TAKING LONGER THAN EXPECTED
    * FINANCIAL FORECAST FOR 2023 ADJUSTED ON OCTOBER 12TH
    * FOR THE YEAR AS A WHOLE, SARTORIUS EXPECTS A DECLINE IN
SALES OF
AROUND 17 PERCENT WITH AN OPERATING EBITDA MARGIN OF JUST OVER
28 PERCENT

Further company coverage:  SATG.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

Recent news on Sartorius Stedim Biotech SA

See all news